mental health AIDS

Fall 2007 Newsletter / Volume 9, Issue 1

HIV Treatment News

Medical Care

On August 6, the U.S. Food and Drug Administration (FDA) approved maraviroc (MVC or Selzentry™), the first in a new class of antiretroviral drugs known as CCR5 co-receptor antagonists. Maraviroc is approved for use in combination with other antiretroviral drugs

for the treatment of adults with CCR5-tropic HIV-1, who have been treated with other HIV medications and who have evidence of elevated levels of HIV in their blood (viral load). Rather than fighting HIV inside white blood cells, maraviroc prevents the virus from entering uninfected cells by blocking the predominant route of entry, the CCR5 co-receptor. CCR5 is a protein on the surface of some types of immune cells. Among patients who have previously received HIV medications, approximately 50 percent to 60 percent have circulating CCR5-tropic HIV-1. ...

The product label includes a boxed warning about liver toxicity (hepatoxicity) and a statement in the Warnings/Precautions section about the possibility of heart attacks. ... The most common adverse events reported with maraviroc were cough, fever, upper respiratory tract infections, rash, musculoskeletal symptoms, abdominal pain, and dizziness. (FDA, 2007)

Indicates this file is in Adobe PDF format and requires the Adobe Acrobat Reader program.

Disclaimer Privacy Policy Accessibility Department of Health and Human Services